Navigation Links
Genedata Announces Aptevo Therapeutics Deploys Genedata Biologics to Streamline Cancer Immunotherapy R&D
Date:8/21/2018

Genedata, a leading provider of advanced software solutions for biopharma R&D, today announced that Seattle-based Aptevo Therapeutics, a clinical-stage biotechnology company, has adopted Genedata as their preferred bioinformatics solution provider. Aptevo will use the Genedata Biologics® platform to facilitate expansion of their pipeline of novel bispecific antibody candidates focused on immuno-oncology, autoimmune disease and inflammation.

“To increase the throughput of our bispecific discovery program we needed a flexible E2E workflow system that could support our proprietary discovery technologies and ADAPTIR™ protein therapeutic platform,” said Dr. Peter Pavlik, Director of Molecular Biology and Protein Engineering Research at Aptevo. “We determined that Genedata Biologics was the best solution to fully address all our unique workflow requirements as it enables scale up of the screening, engineering, production and testing of complex multi-specific antibody candidates.”

“We appreciate Genedata Biologics’ flexible business model, which made it possible for a company of our size to adopt a market-leading platform solution,” said William Benjamin, IT Director at Aptevo. “As an established, off-the-shelf product, Genedata Biologics could be deployed across our organization with minimal customization. Also, this cloud-based solution was particularly appealing because of the rapid implementation it offered. We are very pleased with Genedata’s strong commitment to service and technical support and look forward to a long and productive partnership.”

“We are excited to work with Aptevo, an innovative leader in the development of novel immunotherapies. This partnership illustrates how Genedata works with future industry leaders who need a platform for scale up and automation of their R&D operations as they grow as an organization,” said Dr. Othmar Pfannes, CEO of Genedata. “We are committed to helping our partners – both large and small – be innovative and at the same time efficient.”

Since its first release in 2011, Genedata Biologics has been rapidly adopted by the majority of the world’s leading biopharmaceutical companies, as well as emerging specialty biotech companies. Genedata’s collaborations range from single group installations to large, global, multi-site partnerships and include technology transfer, customizations, project management, training, and roll out and deployment support.

Editorial Note
On August 21 at 11:20 EDT, Genedata Biologics will be featured at the Bispecific Antibody Pipeline Congress in the presentation “Bispecific Platform Designed for Rapid Development and Manufacturing of Novel Protein Therapeutics” by Peter Pavlik, PhD, Principle Scientist, Aptevo Therapeutics.
To schedule a briefing, contact biologics@genedata.com.

About Genedata
Genedata transforms data into intelligence with innovative software solutions and domain-specific consulting services that automate complex, large-scale experimental processes and enable organizations to maximize the ROI from their R&D. Founded in 1997, Genedata is headquartered in Switzerland and has offices in Germany, the UK, Japan, and the US.
http://www.genedata.com
Follow Us on LinkedIn

Disclaimer
The statements in this press release that relate to future plans, events or performance are forward-looking statements that involve risks and uncertainties, including risks associated with uncertainties related to contract cancellations, developing risks, competitive factors, uncertainties pertaining to customer orders, demand for products and services, development of markets for the Company's products and services. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. The Company undertakes no obligation to release publicly the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

All product and service names mentioned are the trademarks of their respective companies.

Read the full story at https://www.prweb.com/releases/genedata_announces_aptevo_therapeutics_deploys_genedata_biologics_to_streamline_cancer_immunotherapy_r_d/prweb15698170.htm.


'/>"/>
Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved


Related biology news :

1. Merck Animal Health announces Vetsulin
2. AAPS announces 2013 National Biotechnology Conference award winners
3. PLOS announces Accelerating Science Award Program
4. DFG announces recipients of 2013 Heinz Maier-Leibnitz Prize
5. Missouri Botanical Garden program announces collaboration with LHerboretum
6. Scripps Research announces research & license agreement with Janssen Pharmaceuticals
7. Chiltern Announces The Promotion Of Alecia Barbee To VP, Global Biometrics
8. DigitalPersona Announces U.are.U Software Development Kit (SDK) for Android Applications
9. PatientStream announces the industrys first Multilingual family waiting room board
10. Wiley announces increase in Impact Factors
11. Xyngular Announces the Launch of its New Xyng Enhanced Formula
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/9/2019)... ... March 08, 2019 , ... Ace ... product, Well-Mints™ resveratrol + ribose hard candy lozenges ( http://www.well-mints.com ). , Well-Mints™ ... naturally flavored hard candy base dusted with powdered sugar. , Well-Mints'™ patented technology ...
(Date:3/1/2019)... (PRWEB) , ... February 28, 2019 , ... Teresa Krabbe, ... der Isar of the Technical University Munich, has been awarded an xCELLigence Research Grant ... an improved oncolytic virus platform. , Oncolytic viruses represent an exciting new ...
(Date:2/22/2019)... ... 2019 , ... RoosterBio, Inc, a privately held regenerative medicine ... Frederick, MD after a year of rapid growth. , “Hundreds of researchers and ... products to streamline their product development efforts in the regenerative medicine field, resulting ...
Breaking Biology News(10 mins):
(Date:3/14/2019)... ... March 14, 2019 , ... Xybion ... research organizations. It is a low code, GDPR/21 CFR Part 11-compliant digital ... technology-driven automated data capture and seamless data and information management. , ...
(Date:3/11/2019)... ... ... In this live webinar, the featured speakers will focus on the many attributes that ... how to use the information they have from the protocol and clinical trial knowledge, ... is properly designed and set up to ensure flawless execution. As clinical trial success ...
(Date:3/9/2019)... SEATTLE (PRWEB) , ... March ... ... source for unbiased college rankings and higher education planning, announced the release ... identifies the top programs in the nation based on curriculum quality, program ...
(Date:3/4/2019)... ... ... of current hot topics through free webinars presented by leading experts in pharma, biotech, medical ... today to save your place! Participate in the discussion and stay relevant in your field! ... , March 20 – Implementing BYOD Across Phase II and III Clinical Trials ...
Breaking Biology Technology: